Total Artificial Heart Implantation Blood Pressure Management as Resolving Treatment for Massive Hemolysis following Total Artificial Heart Implantation

Ali Ghodsizad; Michael M Koerner; A El-Banayosy; Mohamed Zeriouh; Arjang Ruhparwar; Matthias Loebe

doi:10.1532/hsf.1633

Total Artificial Heart Implantation Blood Pressure Management as Resolving Treatment for Massive Hemolysis following Total Artificial Heart Implantation

Heart Surg Forum. 2016 Oct 21;19(5):E229. doi: 10.1532/hsf.1633.

Authors

Ali Ghodsizad^{1

2}, Michael M Koerner³, A El-Banayosy³, Mohamed Zeriouh⁴, Arjang Ruhparwar⁵, Matthias Loebe²

Affiliations

¹ Division of Thoracic Transplantation and MCS, Miami Transplant Institute, University of Miami, Jackson Memoral Hospital, Miami, Flordia, USA.
² Heart and Vascular Institute, Pennstate Milton Hershey Medical Center, Penn State College of Medicine, Hershey Pennsylvania, USA.
³ Department of MCS, Integris Health Nazi Zuhdi Transplant and Advanced Cardiac Institute, Oklahoma City, Oklahoma, USA.
⁴ Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, United Kindom.
⁵ Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.

PMID: 27801302
DOI: 10.1532/hsf.1633

Abstract

The SynCardia Total Artificial Heart (TAH) has been used for patients with biventricular failure, who cannot be managed with implantation of a left ventricular (LV) assist device. Following TAH implantation, our patient developed severe hemolysis, which could only be managed successfully by aggressive blood pressure control [Ohashi 2003; Nakata 1998].

Publication types

Case Reports

MeSH terms

Cardiomyopathy, Dilated / surgery*
Female
Heart, Artificial / adverse effects*
Hemolysis*
Humans
Hypertension / drug therapy*
Hypertension / etiology*
Hypertension / pathology
Middle Aged
Postoperative Complications / drug therapy*
Postoperative Complications / pathology